Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 12/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.71 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17551701 | 0.86 | MAPT (0.66) | PTGS1RXFP1 | |
| SCHEMBL1064825 | 0.85 | HDAC1 (0.76) | HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL1066327 | 0.84 | HDAC1 (0.67) | HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL1689269 | 0.83 | HDAC1 (0.73) | HDAC1PTGS1RXFP1 | |
| SCHEMBL212652 | 0.83 | HDAC1 (0.80) | HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL214711 | 0.82 | HDAC1 (0.64) | HDAC1HDAC2HDAC3NCOR2PTGS1 | |
| SCHEMBL2413774 | 0.82 | PTGS1 (0.78) | HDAC1HDAC2HDAC3NCOR2PTGS1 | |
| SCHEMBL14626487 | 0.81 | PTGS1 (0.58) | HDAC1HDAC2HDAC3NCOR2PTGS1 | |
| SCHEMBL1066331 | 0.80 | HDAC1 (0.71) | HDAC1HDAC2HDAC3NCOR2 | |
| SCHEMBL1065094 | 0.80 | HDAC1 (0.78) | HDAC1HDAC2HDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC2 12/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.